Clinical Trial Update: PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial PRINCE evaluating PSMA-lutetium radioligand therapy combined with immune therapy in metastatic castration-resistant prostate cancer has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Immunotherapy (immunotherapy)
• PSMA-lutetium radioligand therapy (PSMA-targeted radioligand therapy (e.g., lutetium-177-PSMA))

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED